文献速递胸部技术与安全CT

急诊科接受免疫检查点抑制剂治疗患者的胸部CT表现:单机构8年136例经验

Findings on Chest CT Performed in the Emergency Department in Patients Receiving Immune Checkpoint Inhibitor Therapy: Single-Institution 8-Year Experience in 136 Patients.
PubMed 文献 · AJR Am J Roentgenol · 2020-12-09

回顾性分析2011至2018年136例接受免疫检查点抑制剂(ICI)治疗患者在163次急诊就诊中完成的胸部CT,最常见表现为肺肿瘤负荷加重(60.1%)、非肿瘤性新发实变(30.1%)、新发或加重的胸腔积液(23.9%)和ICI相关肺炎(12.9%),其中肿瘤加重与更差生存相关(p=.006),胸腔积液亦与更差生存相关(p=.04)。

要点

  • ICI治疗患者急诊胸部CT最常见表现为肺肿瘤负荷加重(60.1%),且与更差生存相关。
  • 非肿瘤性新发实变(30.1%)和ICI相关肺炎(12.9%)在急诊场景中也较常见。
  • ICI相关肺炎最常见的CT模式为放射性回忆性肺炎(6/21,28.6%)。

关键影像表现/征象

  • 最常见的CT表现为肺肿瘤负荷加重(60.1%)、非肿瘤相关新发实变(30.1%)、新发或加重的胸腔积液(23.9%)和ICI相关肺炎(12.9%)。
  • ICI相关肺炎最常见的CT模式为放射性回忆性肺炎(6/21,28.6%)。

诊断标准与关键数值

  • 读者间一致性kappa值范围为0.66(肿瘤负荷加重)至1.00(多项表现)。
  • 肿瘤负荷加重患者与无加重患者随访时死亡比例分别为72.2%和49.1%(p=.006)。
  • 有胸腔积液患者与无胸腔积液患者随访时死亡比例分别为39.2%和17.5%(p=.04)。

临床应用与阅片要点

  • 了解ICI治疗患者急诊胸部CT可检出的病变,可能有助于放射科医师解读此类影像。
  • 原文未据此给出具体阅片或报告建议。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. Patients undergoing immune checkpoint inhibitor (ICI) therapy may present to the emergency department (ED) with a wide range of immune-related adverse events. OBJECTIVE. The purpose of our study was to evaluate chest CT findings in patients receiving ICI therapy presenting to the ED and to explore these findings' associations with clinical parameters. METHODS. This retrospective study included 136 patients (75 men, 61 women; mean age, 65 ± 12 [SD] years) receiving ICI therapy who underwent chest CT at 163 ED visits between 2011 and 2018. Two radiologists independently reviewed chest CT examinations for various findings and resolved discrepancies by consensus. Clinical parameters, including survival at last available follow-up, were recorded. Chest CT findings were summarized, and interreader agreement was evaluated using kappa coefficients. Associations between CT findings and clinical parameters were explored using Fisher exact, chi-square, Wilcoxon, and Kruskal-Wallis tests. RESULTS. A total of 62.5% of patients had primary lung cancer; 52.9% received nivolumab monotherapy, and 30.1% received pembrolizumab monotherapy. A total of 55.8% of ED visits occurred within 60 days after ICI initiation. The most common CT findings were worsening lung tumor burden (60.1%), new consolidation unrelated to tumor (30.1%), new or worsening pleural effusion (23.9%), and ICI-associated pneumonitis (12.9%). The most common CT pneumonitis pattern was radiation recall pneumonitis (6/21, 28.6%). A total of 78.5% of ED visits with chest CT resulted in hospitalization; 66.9% of patients subsequently died. Survival was worse for patients with, versus without, worsening tumor (72.2% vs 49.1% of patients deceased vs alive at follow-up, p = .006) and for patients with, versus without, pleural effusion (39.2% vs 17.5% of patients deceased vs alive at follow-up, p = .04). Kappa values for interreader agreement of evaluated chest CT findings ranged from 0.66 (worsening tumor burden) to 1.00 (numerous findings). CONCLUSION. Most ED chest CT examinations in patients receiving ICI therapy exhibited worsening lung tumor burden, which was associated with worse survival. New consolidation and ICI-associated pneumonitis (most commonly radiation recall pneumonitis) were also commonly detected in the ED setting. CLINICAL IMPACT. Understanding pathologies detected on chest CT in patients undergoing ICI therapy who present to the ED may guide radiologists in interpreting such imaging.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Smith DA, Radzinsky E, Tirumani SH, et al. Findings on Chest CT Performed in the Emergency Department in Patients Receiving Immune Checkpoint Inhibitor Therapy: Single-Institution 8-Year Experience in 136 Patients. AJR Am J Roentgenol. 2020. PMID: 33295801. doi:10.2214/AJR.20.24758

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。